Search company, investor...


Founded Year



Series A | Alive

Total Raised


Last Raised

$5.27M | 9 mos ago

About M2S

M2S is a digital healthcare company that develops eye care services and platforms, including VROR, a platform that provides ophthalmological examinations using VR equipment and eye-tracking technology.

Headquarters Location

Pankyo 2 Techno Valley No. 324 in Sujeong-gu, Seongnam-si


South Korea


M2S's Product Videos

ESPs containing M2S

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Healthcare Providers Tech

Companies in this market are providing on-demand, personalized treatments addressing a range of ailments. For senior care, these treatments can address chronic conditions from pain to gastrointestinal disorders.

M2S named as Leader among 13 other companies, including Hinge Health, Kaia Health, and XRHealth.

Compete with M2S?

Ensure that your company and products are accurately represented on our platform.

M2S's Products & Differentiators

    VROR EYE Dr.

    Wellness category product, not for medical industry. Provides 10 types of eye-examinations. Consists of VR headset and Kiosk(or Tablet). Results shows your eye-condition in score(0 to 100). If you log in to our system with your own ID, you can track your test result with the date and score which shows your result trend with graph. You can print out the result with printer or check it on your mobile application.

Expert Collections containing M2S

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

M2S is included in 4 Expert Collections, including AR/VR.



1,370 items


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Conference Exhibitors

5,302 items


Senior Care

389 items

Latest M2S News

The SVS Vascular Quality Initiative (SVS VQI) Surpasses 700 Participating Centers and 700,000 Procedures in M2S PATHWAYS Data Pl...

Sep 23, 2020

News provided by Share this article CHICAGO and WEST LEBANON, N.H., Sept. 23, 2020 /PRNewswire/ -- The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) has recently surpassed 700 participating medical centers and 700,000 procedures. The growth in procedures has been driven by a surge in the growth of the number of practices and physicians involved in the SVS VQI. Since its inception in 2011, more than 4,000 providers have joined the initiative and are entering procedures across 14 different vascular registries. Over 100,000 cases and 100 centers were added to the registry in the past year. M2S The SVS VQI is governed by the SVS Patient Safety Organization (SVS PSO), a wholly-owned subsidiary of the Society for Vascular Surgery, which provides oversight of data sharing arrangements, key outcome and quality measure analyses, and dissemination of information to participating providers. The VQI is comprised of vascular surgeons, cardiologists, radiologists, and other specialists who perform vascular procedures collected in the VQI Registries. Participating centers are divided into 18 regional quality groups. These groups meet biannually to discuss initiatives for improving quality of vascular care. "The rapid growth of SVS VQI is a testament to the engagement and dedication of vascular specialists, their commitment to improving the care they deliver to patients and the value they find in the registry," said Dr. Jens Eldrup-Jorgensen, SVS PSO Medical Director. In addition to improving quality within hospitals and outpatient facilities, the VQI supports efforts to reduce costs as well as vascular quality research. The SVS VQI also works with device companies to support device evaluation and post-market device surveillance projects. The SVS PSO partners with M2S to provide its secure, cloud-based database, M2S PATHWAYS for data collection and analysis. The M2S PATHWAYS™ clinical data performance platform can be used to generate the real-time benchmarked reports of major clinical outcomes, including complications, as well as longitudinal tracking of center performance compared to regional and national standards. These reports permit participants to continuously assess themselves compared to an anonymous group of peers on key performance measures. For more information, click here: Media Contact:

M2S Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

M2S Rank

M2S Frequently Asked Questions (FAQ)

  • When was M2S founded?

    M2S was founded in 2017.

  • Where is M2S's headquarters?

    M2S's headquarters is located at Pankyo 2 Techno Valley No. 324 in Sujeong-gu, Seongnam-si, Gyeonggi-do.

  • What is M2S's latest funding round?

    M2S's latest funding round is Series A.

  • How much did M2S raise?

    M2S raised a total of $7.4M.

  • Who are the investors of M2S?

    Investors of M2S include Solidus Investment, CHA Healthcare, Shinhan Capital, SK Securities, Korea Credit Guarantee Fund and 5 more.

  • Who are M2S's competitors?

    Competitors of M2S include Heru and 1 more.

  • What products does M2S offer?

    M2S's products include VROR EYE Dr. and 1 more.

  • Who are M2S's customers?

    Customers of M2S include PHC, Bucheon City Public Healthcare Center and Eulji University.

Compare M2S to Competitors

Otolith Labs

Otolith Labs is developing prescription medical devices for the treatment of vestibular disorders, conditions experienced by millions of Americans. Its flagship product, a patented noninvasive Vestibular System Masking (nVSM) technology, is intended to be the first prescription wearable device for the treatment of chronic vertigo. The device uses precisely tuned vibrations to interact with the acceleration sensors in the inner ear, mitigating the symptoms of vertigo. Otolith is conducting clinical trials to evaluate its nVSM technology as an immediate symptom relief treatment for chronic vertigo associated with vestibular disorders. Otolith Labs was founded in 2015 and is based in Washington, DC.

Luminopia Logo

Luminopia uses virtual reality goggles to correct amblyopia or lazy eye. Its technology also holds the potential to provide a way to detect this condition, which can frequently go undiagnosed. The company was founded in 2015 and is based in Cambridge, Massachusetts.


Dopavision develops a digital therapeutic that aims to slow down myopia progression in children and adolescents through the activation of dopamine. The company was founded in 2017 and is based in Berlin, Germany.

Tilak Healthcare Logo
Tilak Healthcare

Tilak Healthcare specializes in digital healthcare and is dedicated to the development of medically-prescribed video games for the monitoring and follow-up of patients suffering from chronic diseases. The company's application targets ophthalmology with macular diseases, which affect a large number of patients in the aging populations of developed countries.

Caterna Logo

Caterna develops and markets Software-as-a-Service (SaaS) telemetric treatment software for therapeutic applications in ophthalmology.

S-Alpha Therapeutics

S-Alpha Therapeutics is a digital therapeutics company with platform technologies that enable digital devices to treat different diseases. S-Alpha has a pipeline of products in the areas of ophthalmology, neuropsychiatry, cancer, and immunology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.